Economic Burden of Neonatal Abstinence Syndrome Up Sharply

This article originally appeared here.
Share this content:
Economic Burden of Neonatal Abstinence Syndrome Up Sharply
Economic Burden of Neonatal Abstinence Syndrome Up Sharply

THURSDAY, June 15, 2017 (HealthDay News) -- Rates of neonatal abstinence syndrome (NAS) have risen dramatically in recent years -- and so has the cost of treating it, according to a study published online June 14 in Addiction.

The findings are based on pediatric discharge records from more than 4,000 U.S. hospitals.

Between 2003 and 2012, hospital admissions for NAS rose more than four-fold, the researchers found. Those infants ended up with longer hospital stays than newborns hospitalized for other reasons -- 16.57 days, on average, versus 4.98 days. The typical cost was $16,893, versus $5,610. By 2012, NAS was costing the United States nearly $316 million in hospital care. That was up from $61 million in 2003.

"Increased public health initiatives are needed to target, educate, and provide resources for women of reproductive age in order to decrease antenatal drug exposure," the authors write. "Additionally, given the large variation in screening and treatment of NAS, further study is needed to determine the most effective assessment and management strategies. Lastly, novel therapeutic plans aimed at more cost-efficient management should be encouraged."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »